Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.


Related Content

Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come
Patent Cliff Continues in 2014, But Not So Steeply
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
Alzheimer’s Conference Marked By Diversity Of Approaches
Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
APA Update: New Antidepressants Elbow Into Crowded Market
Lilly Pulls The Plug On Next-Gen Antipsychotic
A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts